Retinal Health: Behind the Lab
At Boehringer Ingelheim, our research scientists are exploring diverse ways to prevent, treat, and restore vision loss in patients with retinal diseases. Delve behind the lab to see our scientists spearheading research into novel therapeutics to address retinopathies.
Watch the videos below to gain an insight into what goes on in our labs:
Antibody Discovery and Development
Hear from Biotherapeutics Project Lead, Sarah Low, as she discusses the challenges of delivering antibody-based therapies to the eye and learn about the essential role Jan-Hendrik Grosch and his processing team play in the production and purification of antibodies as potential treatments.
Potency Assays
Come behind the lab to meet Karoline Eppler, an Analytical Project Lead, and Scientist Katharina Künzel, as they show us how they have developed innovative automation technologies to increase the efficiency of drug potency assays and accelerate the time it will take to bring treatments to people with retinal conditions.
Particle Analysis
Join two of our developers, Felix Nikels and Sebastian Kuhn, as they explain their work on particle analysis of drug-product solutions to assess quality and purity, as well as the peculiarities of Intravitreal Treatments (IVTs). Their work ensures the very high standards of quality, safety and efficacy of various IVTs are met as they are developed into prospective treatments to help patients with retinal health conditions.
Retinal Cell Differentiation and Characterization
Meet Principal Research Scientist Seba Almedawar and Computational Biologist Elke Markert as they explain the process of differentiating pluripotent stem cells (IPS cells) into retinal cells as a model for testing retinopathies, and the analysis that follows.